WASHINGTON (dpa-AFX) - Kailera Therapeutics, Inc. (KLRA), a clinical-stage biotechnology company, on Friday announced the pricing of its initial public offering of 39.06 million shares of stock at $16 per share.
The offering is expected to raise gross proceeds of approximately $625 million, before underwriting discounts and expenses.
The company has granted underwriters a 30-day option to purchase up to an additional 5.86 million shares at the offering price, which could increase total proceeds if exercised.
Shares are expected to begin trading on the Nasdaq Global Select Market on April 17, 2026, under the ticker symbol 'KLRA,' with the offering anticipated to close on April 20, 2026, subject to customary closing conditions.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
